FAP and diabetes mellitus: We used the recombinant DPP8 activity assay to test a panel of potential DPP8 inhibitors: one licensed diabetes drug, vildagliptin, and a series of compounds designed to target human DPP IV/8/9 enzymes [28] (Fig. 3b).